Discussion on machine learning technology to predict tacrolimus blood concentration in patients with nephrotic syndrome and membranous nephropathy in real-world settings
Abstract Background Given its narrow treatment window, high toxicity, adverse effects, and individual differences in its use, we collected and sorted data on tacrolimus use by real patients with kidney diseases. We then used machine learning technology to predict tacrolimus blood concentration in or...
Main Authors: | Weijia Yuan, Lin Sui, Haili Xin, Minchao Liu, Huayu Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | BMC Medical Informatics and Decision Making |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12911-022-02089-w |
Similar Items
-
Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial
by: Aikaterini Nikolopoulou, et al.
Published: (2019-09-01) -
Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes
by: Leticia Cuarental, et al.
Published: (2020-07-01) -
Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients
by: Liang S, et al.
Published: (2023-04-01) -
Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy
by: W. Cui, et al. -
Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China
by: Li Zeng, et al.
Published: (2024-01-01)